20S Immunoproteasome, human PBMC
Catalog number: SBB-PP0004, 25 μg
Highly active protein complex that has been purified from human peripheral blood mononuclear cell (PBMC) . Immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer. This immunoproteasome is supplied at >95% purity and experiments should be carried out at 20S immunoproteasome concentrations between 2-5 nM. [1][2][3][4]
In stock
SKU
0004
$245.00
Description
The immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of alpha subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasome these subunits (ß1, ß2, ß5) are replaced by three inducible subunits: PSMB9, PSMB10, and PSMB8, (ß1i, ß2i, ß5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T-Cells. 20S Immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer. This immunoproteasome is purified from human peripheral blood mononuclear cells and is supplied at >95% purity. Cells used as starting material tested negative for hepatitis B surface antigen, antibodies to hepatitis C virus, HIV type 1 antigens, and antibodies to HIV type 1 and 2. Immunoproteasome is commonly associated with the 19S, PA28 α/ß, or the PA28γ regulatory complexes. If choosing to omit PA28 during use, 20S must be chemically activated by addition of 0.035%SDS in final assay buffers.
For Research Use Only, Not For Use In Humans.
Specifications
| Quantity: | 25 μg |
|---|---|
| Molecular Weight: | > 700 kDa |
| Purity: | > 95% SDS-PAGE |
| Storage Buffer: | 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. |
| Storage | Store at −80°C after product arrival. Avoid multiple freeze / thaws. It is recommended to make multiple aliquots after the first thaw. |
Figures & Data
20S Immunoproteasome
Figure 1. 20S Immunoproteasome, SDS-PAGE.
From left to right, increasing amounts of 20S Immunoproteasome loaded onto a 4-20% SDS-PAGE gel, stained with coomassie brilliant blue.
Immunoproteasome Activity
Figure 2. 20S Immunoproteasome vs. 20S Constitutive Proteasome Activity.
20S Immunoproteasome is most active against LLVY-AMC (SBB-PS0010), PAL-AMC (SBB-PS0007), and ANW-AMC (SBB-PS0009) substrates, representing physiologically relevant chemotrypsin-like, β1i, and β5i immunoproteasome activity respectively.
Certificates of Analysis (COA)
Citations & References
1) Wang J, Maldonado MA (Aug 2006). “The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases”. Cellular & Molecular Immunology. 3 (4): 255–61. PMID 16978533.
2) Murata S, Sasaki K, Kishimoto T, Niwa S, Hayashi H, Takahama Y, Tanaka K (Jun 2007). “Regulation of CD8+ T cell development by thymus-specific proteasomes”. Science. 316 (5829): 1349–53. doi:10.1126/science.1141915. PMID 17540904.
3) Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL (May 2001). “26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide”. The EMBO Journal. 20 (10): 2357–66. doi:10.1093/emboj/20.10.2357. PMC 125470free to read. PMID 11350924.
4) Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC (Nov 2010). “Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)”. Proceedings of the National Academy of Sciences of the United States of America. 107 (46): 19985–19990. doi:10.1073/pnas.1014074107. PMC 2993423free to read. PMID 21045130.
